Recombinant mouse monoclonal antibody binds to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM). This anti-GXM antibody (G15) can be useful in the treatment of patients infected by Cryptococcus neoformans.
Figure 1 Gel filtration profile of GXM-TT2 conjugate passing through Sepharose 2B-CL column (1.5 by 30 cm) equilibrated in 0.2 M NaCI.
The GXM in the fractions was monitored by anthrone reaction (optical density at 620 nm).
Figure 2 Indirect immunofluorescence of stationary phase organisms. Single optical sections obtained at 1.6-~m intervals with mAb.
Scale bar represents 10 um.
Devi, S. J., Schneerson, R., Egan, W., Ulrich, T. J., Bryla, D., Robbins, J. B., & Bennett, J. E. (1991). Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infection and immunity, 59(10), 3700-3707.
Figure 3 Serum GXM levels of mice infected i.v. with 1.5 x 10 s C. neoformans. 1 d after infection mice were bled and then given 1.0 mg of either mAb.
Points are the average of five mice; brackets denote SD. P values were calculated by t test relative to the PBS control using Primer of Biostatistic.
Devi, S. J., Schneerson, R., Egan, W., Ulrich, T. J., Bryla, D., Robbins, J. B., & Bennett, J. E. (1991). Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infection and immunity, 59(10), 3700-3707.
Figure 4 To confirm that IgM- and IgA-opsonized C. neoformans was internalized, we examined macrophages-fungus suspensions.
Murine IgM and IgA are opsonic for C. neoformans in the absence of C.
Taborda, C. P., & Casadevall, A. (2002). CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity, 16(6), 791-802.
Figure 5 Blocking of CR3 and Fc Portion of IgG1 Inhibits Phagocytosis.
Phagocytosis of C. neoformans by MH-S cells after opsonization with mAb 18B7 in the presence of Abs to IgG Fc.
Taborda, C. P., & Casadevall, A. (2002). CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity, 16(6), 791-802.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0042CQ | Recombinant Mouse Anti-C. neoformans GXM Antibody (3E5) | ELISA, IF, IHC, FuncS | Mouse IgA |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0042CQ-F(E) | Recombinant Mouse Anti-C. neoformans GXM Antibody Fab Fragment (3E5) | ELISA, IF | Mouse Fab |
FAMAB-0107JF-F(E) | Mouse Anti-C. neoformans GXM Recombinant Antibody (clone G15); Fab Fragment | ELISA, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0042CQ-S(P) | Recombinant Mouse Anti-C. neoformans GXM Antibody scFv Fragment (3E5) | ELISA, IF | Mouse scFv |
FAMAB-0107JF-S(P) | Mouse Anti-C. neoformans GXM Recombinant Antibody (clone G15); scFv Fragment | ELISA, FuncS | Mouse scFv |
There are currently no Customer reviews or questions for FAMAB-0107JF. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.